<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00326664</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00709</org_study_id>
    <secondary_id>NCI-2009-00709</secondary_id>
    <secondary_id>CDR0000476579</secondary_id>
    <secondary_id>PBTC-020</secondary_id>
    <secondary_id>PBTC-020</secondary_id>
    <secondary_id>PBTC-020</secondary_id>
    <secondary_id>U01CA081457</secondary_id>
    <nct_id>NCT00326664</nct_id>
  </id_info>
  <brief_title>AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors</brief_title>
  <official_title>A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of AZD2171 in treating young
      patients with recurrent, progressive, or refractory primary CNS tumors. AZD2171 may stop the
      growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking
      blood flow to the tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine the maximum tolerated dose of AZD2171 in pediatric patients with recurrent,
      progressive, or refractory primary CNS tumors.

      II. Describe the toxicity profile and dose-limiting toxicities of AZD2171 in these patients.

      SECONDARY OBJECTIVES:

      I. Characterize inter-patient variability in the pharmacokinetics of AZD2171 in these
      patients.

      II. Describe changes in circulating endothelial cells (CECs) and circulating endothelial cell
      precursors (CEPs) in patients treated with AZD2171 at different dose levels.

      III. Correlate changes in CECs, CEPs, plasma, serum, and urine levels of proteins with
      angiogenesis, including vascular endothelial growth factor (VEGF) and VEGF receptor, in
      patients treated with AZD2171 at different dose levels.

      IV. Correlate changes in CECs, CEPs, and angiogenic modulators with changes in magnetic
      resonance (MR) perfusion.

      V. Obtain preliminary evidence of biologic activity of AZD2171 by evaluating alterations in
      tissue perfusion, tumor blood flow, and metabolic activity using MR perfusion and diffusion
      imaging, and positron-emission tomography, and correlating these findings with changes in
      tumor size by standard MRI.

      OUTLINE: This is a dose-escalation, multicenter study. Patients are stratified according to
      concurrent enzyme-inducing anticonvulsant drugs (yes vs no).

      Patients receive oral AZD2171 once daily on days 1-28. Treatment repeats every 28 days for up
      to 13 courses in the absence of disease progression or unacceptable toxicity.

      For each stratum, cohorts of 2-6 patients receive escalating doses of AZD2171 until the
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 25% of
      patients experience dose-limiting toxicity. Once the MTD is determined, an additional 6
      patients per stratum are enrolled and treated at the MTD.

      After completion of study, patients are followed at 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose, defined as the dose at which the model estimates that 25% of patients will experience dose-limiting toxicity as measured by NCI CTCAE v4.0</measure>
    <time_frame>42 days</time_frame>
    <description>Estimated using the modified Continual Reassessment Method (CRM).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Childhood Atypical Teratoid/Rhabdoid Tumor</condition>
  <condition>Childhood Central Nervous System Germ Cell Tumor</condition>
  <condition>Childhood Cerebral Anaplastic Astrocytoma</condition>
  <condition>Childhood Cerebral Astrocytoma</condition>
  <condition>Childhood Grade I Meningioma</condition>
  <condition>Childhood Grade II Meningioma</condition>
  <condition>Childhood Grade III Meningioma</condition>
  <condition>Childhood Infratentorial Ependymoma</condition>
  <condition>Childhood Oligodendroglioma</condition>
  <condition>Childhood Spinal Cord Neoplasm</condition>
  <condition>Childhood Supratentorial Ependymoma</condition>
  <condition>Recurrent Childhood Brain Neoplasm</condition>
  <condition>Recurrent Childhood Brain Stem Glioma</condition>
  <condition>Recurrent Childhood Cerebellar Astrocytoma</condition>
  <condition>Recurrent Childhood Cerebral Astrocytoma</condition>
  <condition>Recurrent Childhood Ependymoma</condition>
  <condition>Recurrent Childhood Medulloblastoma</condition>
  <condition>Recurrent Childhood Pineoblastoma</condition>
  <condition>Recurrent Childhood Subependymal Giant Cell Astrocytoma</condition>
  <condition>Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor</condition>
  <condition>Recurrent Childhood Visual Pathway Glioma</condition>
  <arm_group>
    <arm_group_label>Treatment (cediranib maleate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral AZD2171 once daily on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cediranib Maleate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (cediranib maleate)</arm_group_label>
    <other_name>AZD2171</other_name>
    <other_name>AZD2171 Maleate</other_name>
    <other_name>Recentin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed primary CNS tumor

               -  Histologically benign brain tumors (e.g., low-grade glioma) allowed

               -  Histological requirement waived for intrinsic brain stem or diffuse optic pathway
                  tumors, but must have clinical and/or radiographic evidence of progression

          -  Recurrent, progressive, or refractory disease

          -  Absolute neutrophil count &gt;= 1,000/mm^3 (unsupported)

          -  Platelet count &gt;= 75,000/mm^3 (unsupported)

          -  Creatinine =&lt; 1.5 times upper limit of normal (ULN) OR glomerular filtration rate &gt;=
             70 mL/min

          -  Bilirubin =&lt; 1.5 times ULN

          -  ALT =&lt; 2.5 times ULN

          -  Urine dipstick or urinalysis &lt; 1+ protein

          -  Albumin &gt;= 3 g/dL

          -  Karnofsky performance status (PS) 60-100% (&gt; 16 years of age) OR Lansky PS 60-100% (=&lt;
             16 years of age)

          -  Karnofsky/Lansky PS 70-100% for patients at increased risk for compromised LVEF

          -  Hemoglobin &gt;= 8 g/dL (transfusion support allowed)

          -  No overt renal, hepatic, cardiac, or pulmonary disease

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  QTc prolongation =&lt; 500 msec

          -  No other significant ECG abnormality within the past 14 days

          -  No clinically significant, unrelated, systemic illness, including serious infections
             or significant cardiac, pulmonary, hepatic, or other organ dysfunction, that would
             preclude study participation

          -  No uncontrolled hypertension

               -  Defined as systolic and diastolic BP &gt; 95th percentile for age (ages 1-17)

               -  Defined as BP &gt; 140/90 (ages 18 and older)

          -  No New York Heart Association class III or IV disease and Karnofsky/Lansky PS &lt; 70

               -  Class II disease controlled with treatment and increased monitoring is allowed

          -  Recovered from all prior therapy

          -  No prior AZD2171

          -  At least 3 weeks since prior myelosuppressive anticancer chemotherapy (6 weeks for
             nitrosoureas)

          -  More than 1 weeks since prior investigational or biologic agents

               -  If the investigational or biologic agent has a prolonged half-life (&gt; 48 hours),
                  then these patients must be discussed with the study chair prior to registration

          -  No concurrent drugs or biologics with proarrhythmic potential

          -  More than 3 months since last fraction of craniospinal radiotherapy or total-body
             irradiation

          -  More than 4 weeks since last fraction of focal irradiation to symptomatic metastatic
             sites

          -  At least 6 months since prior allogeneic bone marrow transplantation

          -  At least 3 months since prior autologous bone marrow or stem cell transplantation

          -  At least 1 week since prior filgrastim (G-CSF), sargramostim (GM-CSF), or epoetin alfa
             (2 weeks for pegfilgrastim)

          -  No other concurrent investigational agents

          -  Concurrent dexamethasone allowed provided patient is on a stable or decreasing dose
             for â‰¥ 1 week before study entry

          -  No concurrent chemotherapy

          -  No concurrent routine use of G-CSF, GM-CSF, or epoetin alfa

          -  Able to swallow tablets

          -  Any neurologic deficits must be stable for &gt;= 1 week

          -  If the investigational or biologic agent has a prolonged half-life (&gt; 48 hours), then
             these patients must be discussed with the study chair prior to registration

        Exclusion Criteria:

          -  No known curative therapy available
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Kieran</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Brain Tumor Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Medical Center-Mount Zion</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital-Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Brain Tumor Consortium</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2006</study_first_submitted>
  <study_first_submitted_qc>May 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2006</study_first_posted>
  <last_update_submitted>March 4, 2016</last_update_submitted>
  <last_update_submitted_qc>March 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
    <mesh_term>Meningioma</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Rhabdoid Tumor</mesh_term>
    <mesh_term>Pinealoma</mesh_term>
    <mesh_term>Optic Nerve Glioma</mesh_term>
    <mesh_term>Spinal Cord Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maleic acid</mesh_term>
    <mesh_term>Cediranib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

